3D Systems Corp Dossier - Source-backed chat

3D Systems Corp

DDDNYSE

SectorInformation Technology

IndustryTechnology Hardware, Storage & Peripherals

Beta (adjusted)2.15

Intrinsic Value $3.67median of 2 methodsbased on filings through 30 Jun 2026

Market Price $3.60Price as of 30 Sep 2026

Near fair valueIntrinsic value is 2% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $598.1M

Enterprise Value $561.4M

Shares Outstanding 166.1M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

3D Systems Corporation (DDD) is undergoing a critical structural transition, pivoting away from its legacy, commoditized Industrial segment toward higher-margin, mission-critical applications in Healthcare (such as Dental and MedTech) and Aerospace & Defense. While Q1 2026 results demonstrated positive momentum with Healthcare revenue surging 21% YoY and Adjusted EBITDA turning positive at $2.1 million, the company continues to face structural headwinds. The Industrial segment remains in a double-digit decline (-15% YoY in Q1 2026) due to intense global competition and soft customer capex. Furthermore, persistent cash burn and a history of serial equity dilution (including a recent $50 million public offering in June 2026) present ongoing risks to long-term shareholder value. A Hold rating reflects this balance between promising niche growth and severe structural/dilutive pressures.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$4.00

High · most bullish analyst$5.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

The bear case is triggered by a prolonged downturn in customer capital expenditure, further accelerating the decline of the Industrial segment. In this scenario, the Healthcare pivot fails to scale fast enough to offset these losses, and competitive pressures from specialized players intensify. Continued cash burn forces another highly dilutive equity offering by mid-2027, driving the share price back down toward historical lows.

Base CaseCentral scenario

$3.0050%

The base case assumes that Healthcare and Aerospace & Defense growth will continue to slowly absorb the declines in the Industrial segment, keeping total revenue relatively flat to slightly positive. The company is expected to hover around Adjusted EBITDA breakeven for the full year 2026. However, persistent customer capex softness and competitive pricing pressures will limit significant multiple expansion, keeping the stock range-bound as the market monitors execution and cash burn.

Bull CaseUpside scenario

$4.0030%

The bull case relies on the rapid acceleration of the Aerospace & Defense and Healthcare segments, successfully offsetting the structural decline of the legacy industrial business. Under this scenario, the Littleton facility expansion drives high-margin defense contracts, and VSP Orthopedics platform adoption expands. Operational cost-saving initiatives successfully lead to sustained positive Adjusted EBITDA and organic cash flow breakeven, eliminating the need for further dilutive capital raises.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong growth in the Healthcare segment (+21% YoY in Q1 2026), driven by robust demand in Dental and MedTech applications.
Aerospace & Defense segment expansion, supported by strategic investments such as the Littleton facility build-out and favorable U.S. policy tailwinds.
Successful execution of cost-reduction initiatives, helping the company achieve positive Adjusted EBITDA of $2.1 million in Q1 2026.

Key Investment Risks

Structural decline in the Industrial Solutions segment, which fell 15% YoY in Q1 2026 due to commoditization and aggressive competition.
Persistent cash burn and risk of ongoing shareholder dilution, highlighted by the $50 million public offering priced in June 2026.
High customer concentration risk, particularly within the dental aligner market (e.g., Align Technology).

Thesis Invalidation Triggers

Failure to achieve full-year Adjusted EBITDA breakeven in fiscal year 2026.
A sequential decline in Healthcare segment revenue, indicating that the pivot is losing momentum.
An unexpected acceleration in cash burn that forces an additional capital raise prior to mid-2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.